Tags

Type your tag names separated by a space and hit enter

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Sci Rep. 2021 03 31; 11(1):7282.SR

Abstract

Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2-day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2-10) and oral oseltamivir 75 mg/12 h/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients.

Authors+Show Affiliations

Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Ramsis Street, Abbassia Square, Cairo, 11591, Egypt. drhdabbous@gmail.com.Faculty of Medicine, Ain Shams University Research Institute-Clinical Research Centre (MASRI-CRC), Cairo, Egypt.Chest Department, Ain Shams University, Cairo, Egypt.Faculty of Medicine, Ain Shams University Research Institute-Clinical Research Centre (MASRI-CRC), Cairo, Egypt.Faculty of Medicine, Ain Shams University Research Institute-Clinical Research Centre (MASRI-CRC), Cairo, Egypt.Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Ramsis Street, Abbassia Square, Cairo, 11591, Egypt.Community Medicine Department, Ain Shams University, Cairo, Egypt.Tropical Medicine Department, Assiut University, Assiut, Egypt.Tropical Medicine Department, Assiut University, Assiut, Egypt.Tropical Medicine Department, Assiut University, Assiut, Egypt.Chest Department, Ain Shams University, Cairo, Egypt.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33790308

Citation

Dabbous, Hany M., et al. "Safety and Efficacy of Favipiravir Versus Hydroxychloroquine in Management of COVID-19: a Randomised Controlled Trial." Scientific Reports, vol. 11, no. 1, 2021, p. 7282.
Dabbous HM, El-Sayed MH, El Assal G, et al. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci Rep. 2021;11(1):7282.
Dabbous, H. M., El-Sayed, M. H., El Assal, G., Elghazaly, H., Ebeid, F. F. S., Sherief, A. F., Elgaafary, M., Fawzy, E., Hassany, S. M., Riad, A. R., & TagelDin, M. A. (2021). Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Scientific Reports, 11(1), 7282. https://doi.org/10.1038/s41598-021-85227-0
Dabbous HM, et al. Safety and Efficacy of Favipiravir Versus Hydroxychloroquine in Management of COVID-19: a Randomised Controlled Trial. Sci Rep. 2021 03 31;11(1):7282. PubMed PMID: 33790308.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. AU - Dabbous,Hany M, AU - El-Sayed,Manal H, AU - El Assal,Gihan, AU - Elghazaly,Hesham, AU - Ebeid,Fatma F S, AU - Sherief,Ahmed F, AU - Elgaafary,Maha, AU - Fawzy,Ehab, AU - Hassany,Sahar M, AU - Riad,Ahmed R, AU - TagelDin,Mohamed A, Y1 - 2021/03/31/ PY - 2020/09/22/received PY - 2021/02/25/accepted PY - 2021/4/1/entrez PY - 2021/4/2/pubmed PY - 2021/5/4/medline SP - 7282 EP - 7282 JF - Scientific reports JO - Sci Rep VL - 11 IS - 1 N2 - Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2-day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2-10) and oral oseltamivir 75 mg/12 h/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/33790308/Safety_and_efficacy_of_favipiravir_versus_hydroxychloroquine_in_management_of_COVID-19:_A_randomised_controlled_trial. L2 - https://doi.org/10.1038/s41598-021-85227-0 DB - PRIME DP - Unbound Medicine ER -